| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJPAIN.2005.07.003 |
| P698 | PubMed publication ID | 16122956 |
| P50 | author | Qasim Aziz | Q77522324 |
| P2093 | author name string | Clifford J Woolf | |
| Anthony R Hobson | |||
| David G Thompson | |||
| Robert P Willert | |||
| Claire Delaney | |||
| P2860 | cites work | Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review | Q24792228 |
| The spinal phospholipase-cyclooxygenase-prostanoid cascade in nociceptive processing | Q28216388 | ||
| Absence of prostaglandin E2-induced hyperalgesia in NMDA receptor epsilon subunit knockout mice | Q28379551 | ||
| Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity | Q33939152 | ||
| Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord | Q34199035 | ||
| Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen | Q34522380 | ||
| Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery | Q34525866 | ||
| Evolving pathophysiologic models of functional gastrointestinal disorders | Q34676855 | ||
| Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability | Q35027006 | ||
| Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor | Q35080062 | ||
| Analysis of serial measurements in medical research | Q35167613 | ||
| Valdecoxib: a review | Q35174224 | ||
| Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain | Q35953747 | ||
| Visceral pain: a review of experimental studies | Q37939840 | ||
| Role of visceral afferent mechanisms in functional bowel disorders | Q37978358 | ||
| Parecoxib (parecoxib sodium). | Q40599338 | ||
| Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations | Q41459573 | ||
| Inflammatory responses to intradermal injection of platelet activating factor, histamine and prostaglandin E2 in healthy volunteers: a double blind investigation | Q43229124 | ||
| Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome | Q43250132 | ||
| Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord | Q43809089 | ||
| The role of cyclooxygenase-1 and -2 in the rat formalin test | Q43935274 | ||
| Cyclo-oxygenase-2 contributes to central sensitization in rats with peripheral inflammation | Q44589927 | ||
| The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor | Q44779669 | ||
| Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain | Q44802682 | ||
| Antinociception produced by spinal delivery of the S and R enantiomers of flurbiprofen in the formalin test | Q46135927 | ||
| Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition | Q46223466 | ||
| The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans | Q47566218 | ||
| Contribution of central sensitisation to the development of non-cardiac chest pain | Q47586539 | ||
| The induction and maintenance of central sensitization is dependent on N -methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states | Q52237708 | ||
| Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. | Q52864698 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 487-494 | |
| P577 | publication date | 2005-08-24 | |
| P1433 | published in | European Journal of Pain | Q4548992 |
| P1476 | title | Constitutive cyclo-oxygenase-2 does not contribute to the development of human visceral pain hypersensitivity | |
| P478 | volume | 10 |
| Q34144741 | Central sensitization: Implications for the diagnosis and treatment of pain |
| Q33236088 | Effect of valdecoxib pretreatment on pain and secondary hyperalgesia: a randomized controlled trial in healthy volunteers [ISRCTN05282752, NCT00260325] |
| Q41200820 | Evidence of a role for GTP cyclohydrolase-1 in visceral pain |
| Q47578591 | Exploring the neurophysiological basis of chest wall allodynia induced by experimental oesophageal acidification - evidence of central sensitization. |
| Q37947690 | Optimizing the early phase development of new analgesics by human pain biomarkers |
| Q36728925 | Peripheral and central mechanisms of visceral sensitization in man. |
| Q36728938 | Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity |
| Q38184634 | Translational pain biomarkers in the early development of new neurotherapeutics for pain management |
Search more.